top of page

Company News

Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting

Kelun-Biotech will present the results from six clinical studies at the 2025 ASCO Annual Meeting including for innovative TROP2 ADC, anti-PD-L1 antibody, and novel RET fusion inhibitor.

Image-empty-state.png

April 24, 2025

Kelun-Biotech’s novel ADC drug SKB518 receives IND clearance from U.S. Food and Drug Administration (FDA)

Kelun-Biotech recently receives IND clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for its innovative ADC drug SKB518.

Image-empty-state.png

April 21, 2025

Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 Receives IND Approval from NMPA

Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 receives IND approval from NMPA for clinical trials investigating the treatment of bone metastases in solid tumors.

Image-empty-state.png

March 25, 2025

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in EGFRm NSCLC by NMPA

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) is approved for marketing in its second indication of EGFRm NSCLC by the NMPA.

Image-empty-state.png

March 10, 2025

Kelun-Biotech’s Sacituzumab Tirumotecan (sac-TMT) Study Results Presented At 2025 ASCO Genitourinary Cancers Symposium

Study Results Abstracts for Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) will be presented at 2025 ASCO Genitourinary Cancers Symposium held in San Francisco from February 13-15, 2025.

Image-empty-state.png

February 13, 2025

Kelun-Biotech’s Product Cetuximab N01 Injection Approved For Marketing By NMPA Of China

Kelun-Biotech’s biosimilar product Cetuximab N01 Injection (达泰莱®, formerly A140) was approved for marketing by NMPA of China.

Image-empty-state.png

February 7, 2025

Kelun-Biotech’s Product Tagitanlimab Approved for Marketing for Second Indication in China

Kelun-Biotech’s tagitanlimab approved for marketing for second indication in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic NPC.

Image-empty-state.png

January 21, 2025

Kelun-Biotech’s Novel ADC SKB445 Receives IND Approval from NMPA in China

Kelun-Biotech's innovative ADC SKB445 receives IND approval from NMPA in China.

Image-empty-state.png

January 21, 2025

Kelun-Biotech’s HER2 ADC Trastuzumab botidotin (A166) Second NDA Accepted By NMPA

The second NDA for Kelun-Biotech's innovative HER2 ADC (trastuzumab botidotin) was formally accepted by the NMPA in China.

Image-empty-state.png

January 7, 2025

Kelun-Biotech's Anti-PD-L1 (Tagitanlimab) Receives NMPA Approval for Marketing

Kelun-Biotech's Anti-PD-L1 (Tagitanlimab, 科泰莱®) approved for marketing by NMPA of China for 3L+ nasopharyngeal carcinoma.

Image-empty-state.png

December 31, 2024

Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT, 佳泰莱®) Granted First Marketing Approval in China

Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT, 佳泰莱®) approved for marketing by NMPA of China for 2L+ advanced or metastatic TNBC.

Image-empty-state.png

November 27, 2024

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA for EGFR-mutant NSCLC Accepted by NMPA

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA for locally advanced or metastatic EGFR-mutant NSCLC.

Image-empty-state.png

October 31, 2024

©2023 by KLUS Pharma Inc.

bottom of page